These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26149041)

  • 41. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
    Vandvik PO; Lincoff AM; Gore JM; Gutterman DD; Sonnenberg FA; Alonso-Coello P; Akl EA; Lansberg MG; Guyatt GH; Spencer FA
    Chest; 2012 Feb; 141(2 Suppl):e637S-e668S. PubMed ID: 22315274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
    Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
    Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH;
    Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L
    Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined antiplatelet therapy: still a sweeping combination in cardiology.
    Manolis AS; Manolis TA; Papadimitriou P; Koulouris S; Melita H
    Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):136-67. PubMed ID: 23597106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.
    Coccheri S
    Drugs; 2010 May; 70(7):887-908. PubMed ID: 20426498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
    Bhandari B; Mehta B
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.
    Stegner D; Haining EJ; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1615-20. PubMed ID: 24925975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.
    Cheng JW
    Vasc Health Risk Manag; 2016; 12():263-8. PubMed ID: 27366081
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiplatelet agents and anticoagulants for hypertension.
    Shantsila E; Kozieł-Siołkowska M; Lip GY
    Cochrane Database Syst Rev; 2022 Jul; 7():CD003186. PubMed ID: 35900898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease.
    Nusca A; Patti G; Di Sciascio G
    J Cardiovasc Transl Res; 2013 Jun; 6(3):346-54. PubMed ID: 23283759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Editorial: Paving the way for improved antiplatelet therapy.
    Grove EL
    Curr Pharm Des; 2012; 18(33):5195-6. PubMed ID: 22724421
    [No Abstract]   [Full Text] [Related]  

  • 53. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
    Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenetics of the antiplatelet effect of aspirin.
    Würtz M; Kristensen SD; Hvas AM; Grove EL
    Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
    Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
    J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention.
    Luo L; Fu M; Li Y; Chen Z; Yu J; Luo J; Hu S; Tu L; Xu X
    Clin Cardiol; 2020 Mar; 43(3):235-241. PubMed ID: 31777973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.